- Greene, Sarah E;
- Huang, Yuefang;
- Kim, Wooseob;
- Liebeskind, Mariel J;
- Chandrasekaran, Vinay;
- Liu, Zhuoming;
- Deepak, Parakkal;
- Paley, Michael A;
- Lew, Daphne;
- Yang, Monica;
- Matloubian, Mehrdad;
- Gensler, Lianne S;
- Nakamura, Mary C;
- O'Hallaran, Jane A;
- Presti, Rachel M;
- Whelan, Sean PJ;
- Buchser, William J;
- Kim, Alfred HJ;
- Weil, Gary J
Objective
Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination.Methods
We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA.Results
The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA.Conclusions
This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.